Taconic Capital Advisors’s Aspire Biopharma Warrant ASBPW Stock Holding History

Taconic Capital Advisors’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-300,000	Closed	-$13.4K	–	80
2025 Q2	$13.4K	Hold	300,000	–	–	﹤0.01%	61
2025 Q1	$20.3K	Hold	300,000	–	–	﹤0.01%	54
2024 Q4	$14.3K	Hold	300,000	–	–	﹤0.01%	57
2024 Q3	$12.7K	Hold	300,000	–	–	﹤0.01%	53
2024 Q2	$9.03K	Hold	300,000	–	–	﹤0.01%	70
2024 Q1	$9.03K	Hold	300,000	–	–	﹤0.01%	79
2023 Q4	$18K	Hold	300,000	–	–	﹤0.01%	92
2023 Q3	$15K	Hold	300,000	–	–	﹤0.01%	122
2023 Q2	$15K	Hold	300,000	–	–	﹤0.01%	169
2023 Q1	$12.5K	Hold	300,000	–	–	﹤0.01%	237
2022 Q4	$24K	Hold	300,000	–	–	﹤0.01%	369
2022 Q3	$36K	Hold	300,000	–	–	﹤0.01%	464
2022 Q2	$36K	Buy	+300,000	New	+$65.3K	﹤0.01%	528

Other funds holding ASBPW

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Taconic Capital Advisors's ASBPW Position: Q3 2025 in Review

Taconic Capital Advisors sold out of Aspire Biopharma Warrant (ASBPW) in Q3 2025, closing a stake of 300,000 shares — an estimated $13.4K sold.

Taconic Capital Advisors first reported a position in ASBPW in Q2 2022 and held it in 13 quarters. The position peaked at $36K in Q3 2022. 29 funds tracked by Wall St. Rank hold ASBPW as of Q3 2025.

Taconic Capital Advisors reported no remaining Aspire Biopharma Warrant position as of Q3 2025 after selling out during the quarter.
Taconic Capital Advisors sold 300,000 Aspire Biopharma Warrant shares in Q3 2025, an estimated $13.4K.
Taconic Capital Advisors first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 13 quarters.
Taconic Capital Advisors's Aspire Biopharma Warrant position peaked at $36K in Q3 2022.
29 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q3 2025.

Based on Taconic Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.